Document is current

Documents that mention this clinical trial

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780

IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba8035

IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.
https://doi.org/10.1200/jco.2023.41.16_suppl.8522

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
https://doi.org/10.1136/jitc-2023-007047

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
https://doi.org/10.1200/jco-24-01681

Documents that mention this clinical trial

Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924

Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
https://doi.org/10.1136/bmjonc-2023-000128

584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab
https://doi.org/10.1136/jitc-2022-sitc2022.0584

435 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0435

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
https://doi.org/10.1016/s0140-6736(16)00587-0

Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
https://doi.org/10.1136/jitc-2024-010578

26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials
https://doi.org/10.1136/jitc-2021-sitc2021.026

46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
https://doi.org/10.1136/jitc-2023-sitc2023.0046

Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC
https://doi.org/10.1136/jitc-2025-013098

28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology
https://doi.org/10.1136/jitc-2021-sitc2021.028

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

1090 Cross-cancer immunotherapy response prediction with the CURE AI foundation model
https://doi.org/10.1136/jitc-2025-sitc2025.1090

Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727

hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
https://doi.org/10.1136/jitc-2023-006913

329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials
https://doi.org/10.1136/jitc-2021-sitc2021.329

Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
https://doi.org/10.1136/jitc-2023-007047

Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
https://doi.org/10.1200/jco.2024.42.16_suppl.2607

831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research
https://doi.org/10.1136/jitc-2021-sitc2021.831

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
https://doi.org/10.1136/jitc-2019-000500

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
https://doi.org/10.1136/jitc-2020-001882

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231